Miller–Fisher syndrome after coronary artery bypass surgery

Miller–Fisher syndrome (MFS) is an uncommon neurological disorder that is considered a variant of the Guillain–Barre syndrome (GBS). It is clinically defined by a triad of symptoms, namely ataxia, areflexia and ophthalmoplegia. These acute inflammatory polyradiculopathic syndromes can be triggered b...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular Journal of Africa 2017-11, Vol.28 (6), p.e4-e5
Main Authors: Albeyoglu, Sebnem, Kutlu, Hakan, Aldag, Mustafa, Ciloglu, Ufuk, Ceylan, Levent
Format: Article
Language:English
Subjects:
Angina pectoris
Ataxia
Cardiopulmonary bypass
Cardiovascular disease
Case Report
Coronary artery bypass grafting
Coronary vessels
Guillain-Barre syndrome
Heart surgery
Hospitals
Immunoglobulins
Miller–Fisher syndrome
NMR
Nuclear magnetic resonance
Stents
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Miller–Fisher syndrome (MFS) is an uncommon neurological disorder that is considered a variant of the Guillain–Barre syndrome (GBS). It is clinically defined by a triad of symptoms, namely ataxia, areflexia and ophthalmoplegia. These acute inflammatory polyradiculopathic syndromes can be triggered by viral infections, major surgery, pregnancy or vaccination. While the overall incidence of GBS is 1.2–2.3 per 100 000 per year, MFS is a relatively rare disorder. Only six cases of GBS after cardiac surgery have been reported, and to our knowledge, we describe the first case of MFS after coronary artery bypass surgery. Although cardiac surgery with cardiopulmonary bypass may increase the incidence of MFS and GBS, the pathological mechanism is unclear. Cardiac surgery may be a trigger for the immune-mediated response and may cause devastating complications. It is also important to be alert to de novo autoimmune and unexpected neurological disorders such as MFS after coronary bypass surgery.
ISSN:1995-1892
1680-0745
DOI:10.5830/CVJA-2017-033